GlaxoSmithKline PLC (GSK) : Analyst Rating Update

GlaxoSmithKline PLC (GSK) : 5 analysts are covering GlaxoSmithKline PLC (GSK) and their average rating on the stock is 2.6, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

GlaxoSmithKline PLC (GSK) : Average target price received by GlaxoSmithKline PLC (GSK) is $48.5 with an expected standard deviation of $0.71. The most aggressive target on the stock is $49, whereas the most downbeat target is $48. 2 financial analysts are currently covering the stock.

GlaxoSmithKline PLC (NYSE:GSK): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $43.08 and $42.99 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $43.70. The buying momentum continued till the end and the stock did not give up its gains. It closed at $43.65, notching a gain of 0.34% for the day. The total traded volume was 3,214,604 . The stock had closed at $43.50 on the previous day.

The company shares have rallied 5.17% from its 1 Year high price. On Aug 6, 2015, the shares registered one year high at $45.49 and the one year low was seen on Sep 29, 2015. The 50-Day Moving Average price is $41.97 and the 200 Day Moving Average price is recorded at $41.03.

GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its human immunodeficiency virus (HIV) business is managed through ViiV Healthcare. GSKs Vaccines has a portfolio of over 30 paediatric, adolescent, adult travel vaccines. GSKs Established Products Portfolio includes over 50 off-patent products, as well as its branded generics business and other local products. The Consumer Healthcare business develops and markets products in four categories, such as wellness, oral health, nutrition and skin health. Its brands include Sensodyne, Panadol, Horlicks, Polident, Paradontax, Tums, ENO, NiQuitin/Nicorette, Abreva, Zovirax and Aquafresh. It operates in the United Kingdom, the United States, Belgium and China.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.